SEC Tracker
Get the app

Braveheart Bio BRVE

Braveheart Bio reports Q3 2026 financial results

Braveheart Bio (BRVE) filed an 8-K with the SEC on Nov 10, 2026, 4:06 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents and investments of $503.5 million
  2. LIONHEART-HCM Phase 3 enrolling with interim analysis expected in 2027
  3. NOBLEHEART-HCM Phase 3 in nHCM on track to initiate in 2027
  4. TRUEHEART-HCM Phase 2b fixed-dose trial to start in 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Braveheart Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.